Next Article in Journal
Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility
Next Article in Special Issue
Special Issue: Monoclonal Antibodies
Previous Article in Journal
Evaluation of Continuous Membrane Chromatography Concepts with an Enhanced Process Simulation Approach
Previous Article in Special Issue
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
Article Menu

Export Article

Open AccessReview
Antibodies 2018, 7(1), 14; https://doi.org/10.3390/antib7010014

Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H

1
Nanomedicine Research and Education Center, Semmelweis University, 1089 Budapest, Hungary
2
SeroScience Ltd., 1089 Budapest, Hungary
3
Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc University, 3515 Miskolc, Hungary
4
Complement Research Group, Department of Immunology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary
5
MTA-ELTE Immunology Research Group, Department of Immunology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary
*
Authors to whom correspondence should be addressed.
Received: 24 December 2017 / Revised: 1 March 2018 / Accepted: 8 March 2018 / Published: 14 March 2018
(This article belongs to the Special Issue Monoclonal Antibodies)
Full-Text   |   PDF [533 KB, uploaded 14 March 2018]   |  

Abstract

Human application of monoclonal antibodies (mAbs), enzymes, as well as contrast media and many other particulate drugs and agents referred to as “nanomedicines”, can initiate pseudoallergic hypersensitivity reactions, also known as infusion reactions. These may in part be mediated by the activation of the complement system, a major humoral defense system of innate immunity. In this review, we provide a brief outline of complement activation-related pseudoallergy (CARPA) in general, and then focus on the reactions caused by mAb therapy. Because the alternative pathway of complement activation may amplify such adverse reactions, we highlight the potential use of complement factor H as an inhibitor of CARPA. View Full-Text
Keywords: CARPA; complement; complement activation; factor H; hypersensitivity; infusion reaction; monoclonal antibody therapy; pseudoallergic reaction CARPA; complement; complement activation; factor H; hypersensitivity; infusion reaction; monoclonal antibody therapy; pseudoallergic reaction
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Fülöp, T.; Mészáros, T.; Kozma, G.T.; Szebeni, J.; Józsi, M. Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H. Antibodies 2018, 7, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top